er stopping their current high blood pressure medication, patients
received a single-pill combination of either Lotrel or a combination of
benazepril and HCTZ. In the first two months of the study, doses of study
medications were increased. Patients in the Lotrel arm started on 5/20 mg.
The dose was increased to Lotrel 5/40 mg and, for patients not at goal
blood pressure, then to 10/40 mg. Patients taking benazepril and HCTZ
started at 20/12.5 mg and were increased to 40/12.5 mg and, for patients
not at goal blood pressure, to 40/25 mg. The combination doses of
benazepril and HCTZ 40/12.5 mg and 40/25 mg used in this study were
investigational. In both arms, patients were given additional blood
pressure medication if goal blood pressure was not attained on the maximum
dose of study medications.
The primary study endpoint was a composite of cardiovascular disease,
non- fatal heart attack, non-fatal stroke, and hospitalization for unstable
angina (chest pain that occurs when the heart muscle does not get enough
blood) or revascularization (a procedure that re-establishes blood flow to
previously restricted regions of the heart), and cardiovascular death. The
full data will be available later this year and further analyses will
examine the effects on specific patient populations.
Important safety information
LOTREL and the fixed dose combination of benazepril and HCTZ are
prescription medications for the treatment of high blood pressure. They
should not be used before other high blood pressure medications have been
tried first.
LOTREL and the fixed dose combination of benazepril and HCTZ can harm
an unborn baby and even cause death. If you get pregnant, stop taking
LOTREL or the benazepril and HCTZ combination. Call your doctor right away.
Talk to your doctor about other ways to lower your blood pressure if you
plan to become pregnant.
Don't take LOTREL or the benazepril and HCTZ combination if you are
allergic to any of the ingredien
'/>"/>
SOURCE Novartis Pharmaceuticals Corporation Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 Related medicine technology :1.
Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL2.
ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)3.
New 48-Week Efficacy and Safety Data Presented for INTELENCE(TM) (etravirine) as Part of HIV Combination Therapy4.
Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-21685.
First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine6.
Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma7.
Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C8.
New Drug Combination is Able to Eradicate Breast Metastases in Mice9.
Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma10.
Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation11.
Avicena Announces Positive Phase II Data for a Combination Trial Involving AL-08 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)